[{"data":1,"prerenderedAt":238},["ShallowReactive",2],{"$f1p0q1mihb01kp":3},{"schema":4,"slug":5,"series":6,"series_slug":7,"name":8,"year":9,"therapeutic_area":10,"generated_at":11,"counts":12,"top_targets":23,"top_modalities":56,"top_diseases":82,"top_companies":114,"key_results":142,"trends":227,"previous_editions":236,"comparison":147,"highlighted_classes":237},1,"ers-2026","ERS","ers","ERS Congress 2026",2026,"Pulmonology","2026-11-05T22:19:09Z",{"abstracts":13,"drug_linked":14,"companies":15,"by_phase":16},5365,1093,204,{"Phase 1":17,"Phase 1\u002F2":18,"Phase 2":19,"Phase 4":20,"Phase 2\u002F3":21,"Phase 3":22},33,4,40,8,2,56,[24,28,31,35,38,41,44,47,51,53],{"name":25,"count":26,"share":27},"GR",112,10,{"name":29,"count":30,"share":20},"ADRB2",91,{"name":32,"count":33,"share":34},"IL4R",62,6,{"name":36,"count":22,"share":37},"IL13RA1",5,{"name":39,"count":40,"share":37},"CHRM3",53,{"name":42,"count":43,"share":37},"IL-5",50,{"name":45,"count":46,"share":18},"TSLP",42,{"name":48,"count":49,"share":50},"PDGFRA",37,3,{"name":52,"count":49,"share":50},"PDGFRB",{"name":54,"count":55,"share":50},"IL5RA",36,[57,61,65,67,70,73,76,79],{"name":58,"count":59,"share":60},"Small molecules",694,63,{"name":62,"count":63,"share":64},"Monoclonal antibodies",261,24,{"name":66,"count":30,"share":20},"Non-antibody therapeutic proteins",{"name":68,"count":69,"share":50},"Carbohydrate, lipid and polymer therapeutics",31,{"name":71,"count":72,"share":50},"Natural-product mixtures and botanicals",28,{"name":74,"count":75,"share":21},"Peptides",26,{"name":77,"count":78,"share":21},"Vaccines",25,{"name":80,"count":81,"share":21},"Blood, tissue and cell-derived products",17,[83,86,90,94,97,100,102,105,108,111],{"name":84,"count":85,"share":64},"asthma",259,{"name":87,"count":88,"share":89},"chronic obstructive pulmonary disease (COPD)",197,18,{"name":91,"count":92,"share":93},"idiopathic pulmonary fibrosis (IPF)",132,12,{"name":95,"count":96,"share":34},"pulmonary fibrosis (PF)",71,{"name":98,"count":99,"share":18},"interstitial lung disease (ILD)",47,{"name":101,"count":49,"share":50},"pulmonary arterial hypertension (PAH)",{"name":103,"count":104,"share":50},"eosinophilic asthma (EA)",34,{"name":106,"count":107,"share":50},"bronchiectasis",30,{"name":109,"count":110,"share":50},"cystic fibrosis (CF)",29,{"name":112,"count":113,"share":21},"non-small cell lung cancer (NSCLC)",22,[115,119,121,124,127,130,133,135,137,139],{"name":116,"count":117,"share":118},"AstraZeneca",115,11,{"name":120,"count":26,"share":27},"GSK",{"name":122,"count":123,"share":37},"Boehringer Ingelheim",60,{"name":125,"count":126,"share":37},"Regeneron Pharmaceuticals",55,{"name":128,"count":129,"share":37},"Pfizer",51,{"name":131,"count":132,"share":18},"Merck",41,{"name":134,"count":64,"share":21},"Chiesi",{"name":136,"count":64,"share":21},"Sanofi",{"name":138,"count":113,"share":21},"Genentech",{"name":140,"count":141,"share":21},"Bristol Myers Squibb",20,[143,151,157,163,170,177,185,191,198,205,212,219],{"title":144,"drug":145,"company":147,"phase":148,"disease":95,"finding":149,"url":150},"Effect of nerandomilast in patients with progressive pulmonary fibrosis (PPF) according to guideline criteria: data from the FIBRONEER-ILD trial",{"name":146,"slug":146},"nerandomilast",null,"Phase 3","Among patients who met guideline criteria, 57 (16.6%) in the placebo group died versus 33 (9.7%) in the nerandomilast 9 mg bid group (HR: 0.55 [0.36, 0.85]) and 31(9.1%) in the nerandomilast 18 mg bid group (HR: 0.54 [0.35, 0.84]).","https:\u002F\u002Fs3.eu-central-1.amazonaws.com\u002Fm-anage.com.storage.ers\u002Fabstracts_2026\u002F124855.pdf",{"title":152,"drug":153,"company":147,"phase":148,"disease":101,"finding":155,"url":156},"Treatment response to sotatercept within 1 year of diagnosis of pulmonary arterial hypertension: subgroup analysis by cardiometabolic comorbidity burden",{"name":154,"slug":154},"sotatercept","Participants with 0 (n=109) or ≥1 (n=211) CMC had a longer time to a first clinical worsening event with sotatercept vs placebo (hazard ratio [95% CI]): 0 CMC 0.13 (0.04–0.43; P\u003C0.0001); ≥1 CMCs 0.29 (0.16–0.54; P\u003C0.0001).","https:\u002F\u002Fs3.eu-central-1.amazonaws.com\u002Fm-anage.com.storage.ers\u002Fabstracts_2026\u002F128347.pdf",{"title":158,"drug":159,"company":120,"phase":148,"disease":87,"finding":161,"url":162},"Impact of airflow obstruction severity on mepolizumab response in COPD with an eosinophilic phenotype: optimising quality of life by timely intervention in patients with GOLD 2 while maintaining exacerbation reduction across all GOLD grades",{"name":160,"slug":160},"mepolizumab","The annualized rate of moderate\u002Fsevere exacerbations was reduced with mepolizumab vs placebo by 22% (BEC ≥150 cells\u002FµL) and 18% (≥300 cells\u002FµL) in patients with GOLD 2 and similarly by 19% (BEC ≥150 cells\u002FµL) and 24% (≥300 cells\u002FµL) in those with GOLD 3+4.","https:\u002F\u002Fs3.eu-central-1.amazonaws.com\u002Fm-anage.com.storage.ers\u002Fabstracts_2026\u002F131689.pdf",{"title":164,"drug":165,"company":147,"phase":167,"disease":87,"finding":168,"url":169},"Metoprolol in Chronic Obstructive Pulmonary Disease without Cardiovascular Disease - a randomized controlled trial",{"name":166,"slug":166},"metoprolol","Phase 4","The primary end point occurred in 27% of patients assigned to metoprolol and in 30% assigned to standard care (hazard ratio 0.87; 95% confidence interval (CI) 0.73-1.05, P = 0.14).","https:\u002F\u002Fs3.eu-central-1.amazonaws.com\u002Fm-anage.com.storage.ers\u002Fabstracts_2026\u002F131756.pdf",{"title":171,"drug":172,"company":147,"phase":167,"disease":174,"finding":175,"url":176},"Clinical asthma remission and nasal polyp outcomes with dupilumab versus omalizumab in patients with severe chronic rhinosinusitis with nasal polyps and uncontrolled asthma: results from EVEREST",{"name":173,"slug":173},"dupilumab","chronic rhinosinusitis with nasal polyps (CRSwNP)","At Wk 24, more patients receiving dupilumab vs omalizumab achieved asthma remission (64.0% vs 40.5%, P\u003C0.0001) and greater NPS improvements independent of asthma remission status.","https:\u002F\u002Fs3.eu-central-1.amazonaws.com\u002Fm-anage.com.storage.ers\u002Fabstracts_2026\u002F126732.pdf",{"title":178,"drug":179,"company":147,"phase":182,"disease":84,"finding":183,"url":184},"Efficacy and Safety of CM326, a Humanized Anti-Thymic Stromal Lymphopoietin (TSLP) Monoclonal Antibody, in Moderate-to-Severe Asthma: A Phase II Randomized, Double-Blind, Placebo-Controlled Trial",{"name":180,"slug":181},"CM326","cm326","Phase 2","Treatment-emergent adverse events (TEAEs) were similar (72.5%-76.5% CM326 vs 75% placebo), with no discontinuations or deaths.","https:\u002F\u002Fs3.eu-central-1.amazonaws.com\u002Fm-anage.com.storage.ers\u002Fabstracts_2026\u002F125667.pdf",{"title":186,"drug":187,"company":147,"phase":182,"disease":174,"finding":189,"url":190},"Lunsekimig for chronic rhinosinusitis with nasal polyps: results from the DUET trial",{"name":188,"slug":188},"lunsekimig","Incidence of treatment-emergent adverse events (TEAEs) was 61.5% with lunsekimig vs 42.5% with pbo; common TEAEs (≥5%) were injection site reaction, viral upper respiratory tract infection, nasopharyngitis, epistaxis, ear pain, and increased creatine phosphokinase.","https:\u002F\u002Fs3.eu-central-1.amazonaws.com\u002Fm-anage.com.storage.ers\u002Fabstracts_2026\u002F131839.pdf",{"title":192,"drug":193,"company":195,"phase":182,"disease":84,"finding":196,"url":197},"VALIANT: a phase 2 trial of the efficacy and safety of verekitug, a thymic stromal lymphopoietin (TSLP) receptor antagonist, for severe asthma",{"name":194,"slug":194},"vereckitug","Upstream Bio","Treatment-emergent adverse event incidence was similar with verekitug (58–62%) vs PBO (66%).","https:\u002F\u002Fs3.eu-central-1.amazonaws.com\u002Fm-anage.com.storage.ers\u002Fabstracts_2026\u002F131551.pdf",{"title":199,"drug":200,"company":147,"phase":182,"disease":87,"finding":203,"url":204},"A Dose-Ranging Study of the Novel PDE3\u002F4 Inhibitor HSK39004 in Patients with COPD Receiving Maintenance Single or Dual Bronchodilators",{"name":201,"slug":202},"HSK39004","hsk39004","The TRAE rate was 6.1% in the 1.5 mg group, lower than that of placebo (7.9%).","https:\u002F\u002Fs3.eu-central-1.amazonaws.com\u002Fm-anage.com.storage.ers\u002Fabstracts_2026\u002F131555.pdf",{"title":206,"drug":207,"company":147,"phase":182,"disease":91,"finding":210,"url":211},"Selective TRPA-1 antagonist in patients with chronic cough and idiopathic pulmonary fibrosis: A phase IIa\u002FIIb randomized, double-blind, placebo-controlled study (BI 1839100)",{"name":208,"slug":209},"BI 1839100","bi-1839100","Daytime CC and cough bouts were also reduced vs PBO (–48.8% vs –18.6%, and –36.8% vs 17.9%, respectively).","https:\u002F\u002Fs3.eu-central-1.amazonaws.com\u002Fm-anage.com.storage.ers\u002Fabstracts_2026\u002F131654.pdf",{"title":213,"drug":214,"company":147,"phase":182,"disease":98,"finding":217,"url":218},"A Phase II, Randomized, Double-blind, Placebo-controlled Trial of Pluripotent Stem Cell-Derived Mesenchymal Stem Cells (CAStem Cells) Injection in the Treatment of Acute Exacerbation of Interstitial Lung Disease (AE-ILD)",{"name":215,"slug":216},"CAStem cells","castem-cells","At 3 months, AE-ILD progression-related mortality remained 0% in the CAStem Cell groups, significantly lower than in the placebo group (20%, P = 0.032).","https:\u002F\u002Fs3.eu-central-1.amazonaws.com\u002Fm-anage.com.storage.ers\u002Fabstracts_2026\u002F127230.pdf",{"title":220,"drug":221,"company":147,"phase":224,"disease":87,"finding":225,"url":226},"A phase Ib\u002FIIa study of the anti-ST2 monoclonal antibody 9MW1911 in former smokers with moderate-to-severe COPD",{"name":222,"slug":223},"9MW1911","9mw1911","Phase 1\u002F2","The most common TEAE was upper respiratory tract infection (18.3% in 9MW1911 vs. 25.0% in placebo).","https:\u002F\u002Fs3.eu-central-1.amazonaws.com\u002Fm-anage.com.storage.ers\u002Fabstracts_2026\u002F125705.pdf",{"summary":228,"bullets":230},[229],"Small molecules were the most frequent modality (63% of drug-linked abstracts). GR was the most frequent target (10%). Asthma was the most frequent disease (24%).",[231,232,233,234,235],"AstraZeneca had the largest company share (11% of drug-linked abstracts).","Monoclonal antibodies were the next most frequent modality (24%).","ADRB2 was the next most frequent target (8%).","Chronic obstructive pulmonary disease (COPD) was the next most frequent disease (18%).","GSK had the next largest company share (10%).",[],[],1793970603103]